An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

  • Interventional
  • Not Recruiting
  • NCT03335540
Eligibility Details Visit Clinicaltrials.gov

ADaptiVe Biomarker Trial That InformS Evolution of Therapy

The purpose of this study is to evaluate the treatment of solid tumors with various immunotherapy combinations. The treatment will be determined based upon a broad biomarker assessment.

Gender
All

Age Group
18 Years and up

Accepting Healthy Volunteers?
No

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

        Inclusion Criteria:

         - Participants must have an ECOG performance status of less than or equal to 1

         - Participants must have had prior therapy;Participants who have received adjuvant or neoadjuvant anti-PD(L)1 therapy andprogressed within 6 months of completing therapy will be considered IO refractory.

         - Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1

        Exclusion Criteria:

         - Participants with suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease

         - Participants with carcinomatous meningitis

         - Participants with other active malignancy requiring concurrent intervention

        Other protocol defined inclusion/exclusion criteria could apply

At a Glance

National Government IDNCT03335540

IRB#IRB17-0732

Lead SponsorBristol-Myers Squibb

Lead PhysicianRandy Sweis

Collaborator(s)N/A

EligibilityAll
18 Years and up
Not Recruiting